Andere Sprachen Exscientia plc

Aktien

A3C4QW

US30223G1022

EXAI

Biotechnologie

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:52:32 18.09.2024			% 5 Tage	% 1. Jan.
5,340 ^USD	+6,16 %		+4,79 %	-18,10 %

04.09.	Transcript : Exscientia plc Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 07:00 AM
15.08.	Exscientia plc meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2024	CI

Andere Sprachen

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

100% kostenlose Registrierung

Exscientia participera à la 22e conférence annuelle de Morgan Stanley sur les soins médicaux dans le monde	28.08.
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	28.08.
Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024	15.08.
Exscientia Business Update for Second Quarter and First Half 2024	15.08.
Exscientia plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	15.08.
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results	09.08.
Exscientia : TRANSACTION AGREEMENT EXSCIENTIA PLC RECURSION PHARMACEUTICALS, INC Form 6 K	08.08.
Sector Update: Health Care Stocks Higher in Afternoon Trading	08.08.
Recursion Pharmaceuticals, Exscientia Shares Rise as Companies Agree to Combine	08.08.
Recursion Pharmaceuticals, Inc. Announces to Appoint David Hallett, Ph.D as Chief Scientific Officer	08.08.
Biotech firm Recursion to buy smaller peer Exscientia for $688 million	08.08.
Exscientia acquiert les droits complets d’un inhibiteur potentiel de CDK7, le meilleur de sa catégorie, avant la publication des données de dose croissante de phase 1	18.07.
Exscientia to Acquire Full Control of Cancer Drug Program From GT Apeiron	18.07.
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout	18.07.
Exscientia Expands Amazon Web Services Partnership to Support Drug Discovery Platform	10.07.
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery	10.07.
Exscientia plc Launches Amazon Web Service AI-Powered Platform to Advance Drug Discovery	10.07.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia	25.06.
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm	25.06.
EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline	25.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Exscientia plc

Aktien

A3C4QW

US30223G1022

EXAI

Biotechnologie

Andere Sprachen

Filter